SE443716B - Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor - Google Patents
Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitorInfo
- Publication number
- SE443716B SE443716B SE7805707A SE7805707A SE443716B SE 443716 B SE443716 B SE 443716B SE 7805707 A SE7805707 A SE 7805707A SE 7805707 A SE7805707 A SE 7805707A SE 443716 B SE443716 B SE 443716B
- Authority
- SE
- Sweden
- Prior art keywords
- pyrazolo
- pyridine
- ethyl
- pharmaceutically acceptable
- phosphodiesterase inhibitor
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 230000002401 inhibitory effect Effects 0.000 title claims description 3
- 239000008280 blood Substances 0.000 title description 18
- 210000004369 blood Anatomy 0.000 title description 18
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title description 12
- 239000003112 inhibitor Substances 0.000 title description 3
- 238000005204 segregation Methods 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 36
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 31
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- 229960000278 theophylline Drugs 0.000 claims description 12
- 229960002768 dipyridamole Drugs 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 10
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical group C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 9
- 102000016736 Cyclin Human genes 0.000 claims description 7
- 108050006400 Cyclin Proteins 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical group O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical group C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical group [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- ZOWYFYXTIWQBEP-UHFFFAOYSA-N 1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxyisoquinoline Chemical compound C1=C(OCC)C(OCC)=CC=C1CC1=NC=CC2=CC(OCC)=C(OCC)C=C12 ZOWYFYXTIWQBEP-UHFFFAOYSA-N 0.000 claims description 2
- PHOQGTWDVPGPJO-UHFFFAOYSA-N 2-(4-chloro-1-ethyl-3-methylpyrazolo[3,4-b]pyridin-5-yl)acetonitrile Chemical compound N#CCC1=CN=C2N(CC)N=C(C)C2=C1Cl PHOQGTWDVPGPJO-UHFFFAOYSA-N 0.000 claims description 2
- JYARBGGPLKDNRV-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC(CN(C)C)C(=O)C2=CC(OC)=CC=C21 JYARBGGPLKDNRV-UHFFFAOYSA-N 0.000 claims description 2
- ZQEAOLDJTCZWIH-UHFFFAOYSA-N 2-methyl-6-phenyl-4-piperidin-1-ylpyrazolo[3,4-b]pyridine Chemical compound N=1C2=NN(C)C=C2C(N2CCCCC2)=CC=1C1=CC=CC=C1 ZQEAOLDJTCZWIH-UHFFFAOYSA-N 0.000 claims description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003556 aminophylline Drugs 0.000 claims description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 125000006309 butyl amino group Chemical group 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- KUKBQDRNIFJRLX-UHFFFAOYSA-N ethyl 1-ethyl-3-methyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=C(C)C2=C1NN=C(C)C KUKBQDRNIFJRLX-UHFFFAOYSA-N 0.000 claims description 2
- 150000002537 isoquinolines Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960001789 papaverine Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 claims description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- RDEGFHUPHVYMOD-UHFFFAOYSA-N 11-oxa-2,4,5-triazatricyclo[7.3.0.03,7]dodeca-1(12),2,4,6,8-pentaen-10-one Chemical compound N1=C2N=NC=C2C=C2C(=O)OC=C21 RDEGFHUPHVYMOD-UHFFFAOYSA-N 0.000 claims 1
- FWFVOHOJYQEBDV-UHFFFAOYSA-N 11h-pyrido[4,3-b][1,5]benzodiazepine Chemical compound C1=NC2=CC=CC=C2NC2=CC=NC=C21 FWFVOHOJYQEBDV-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 claims 1
- ISFDRJXUWTUUMS-UHFFFAOYSA-N n'-(4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)ethane-1,2-diamine Chemical compound C=12SC=CC2=NC(NCCN)=NC=1N1CCOCC1 ISFDRJXUWTUUMS-UHFFFAOYSA-N 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 52
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 230000002744 anti-aggregatory effect Effects 0.000 description 13
- 230000000304 vasodilatating effect Effects 0.000 description 12
- 229960001123 epoprostenol Drugs 0.000 description 11
- 210000002435 tendon Anatomy 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940095074 cyclic amp Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QCOZYUGXYJSINC-UHFFFAOYSA-N 1,3,7-trimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C.CN1C(=O)N(C)C(=O)C2=C1N=CN2C QCOZYUGXYJSINC-UHFFFAOYSA-N 0.000 description 1
- SZXKGHSWPXMILO-UHFFFAOYSA-N 10-chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo-[4',3':5,6]pyrido[4,3-b][1,5]benzodiazepin-6(3h)-one Chemical compound CN1C(=O)C2=CN=C3N(CC)N=CC3=C2N(C)C2=CC(Cl)=CC=C21 SZXKGHSWPXMILO-UHFFFAOYSA-N 0.000 description 1
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical class C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- VDYSTDTZDXTLCV-UHFFFAOYSA-N 4-(2,4-dimorpholin-4-ylpyrimido[5,4-d]pyrimidin-6-yl)morpholine Chemical compound C1COCCN1C1=NC=C(N=C(N=C2N3CCOCC3)N3CCOCC3)C2=N1 VDYSTDTZDXTLCV-UHFFFAOYSA-N 0.000 description 1
- CGJSSCMIRBKUPH-UHFFFAOYSA-N 4-(butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5h-furo-[3,4-e]pyrazolo[3,4-b]pyridin-5-one Chemical compound CCCCNC1=C2C(=O)OC(O)C2=NC2=C1C=NN2CC CGJSSCMIRBKUPH-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UOBSYEOJKWEKCT-UHFFFAOYSA-N ethyl 4-(butylamino)-1h-pyrazolo[3,4-b]pyridine-6-carboxylate Chemical compound CCCCNC1=CC(C(=O)OCC)=NC2=C1C=NN2 UOBSYEOJKWEKCT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79900777A | 1977-05-20 | 1977-05-20 | |
| GB3526177 | 1977-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7805707L SE7805707L (sv) | 1978-11-21 |
| SE443716B true SE443716B (sv) | 1986-03-10 |
Family
ID=26262642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7805707A SE443716B (sv) | 1977-05-20 | 1978-05-18 | Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS542335A (enExample) |
| CH (1) | CH643458A5 (enExample) |
| DE (1) | DE2821737A1 (enExample) |
| FR (1) | FR2390964A1 (enExample) |
| HU (1) | HU180548B (enExample) |
| IT (1) | IT1105506B (enExample) |
| NL (1) | NL7805402A (enExample) |
| SE (1) | SE443716B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA787353B (en) * | 1978-05-17 | 1980-08-27 | Wellcome Found | Pharmaceutical formulations |
| DE3526362A1 (de) * | 1985-07-19 | 1987-01-22 | Schering Ag | Prostacycline, ihre analoga oder prostaglandine und thromboxanantagonisten zur behandlung von thrombotischen und thromboembolischen krankheitsbildern |
| ATE80314T1 (de) * | 1987-07-14 | 1992-09-15 | Sankyo Co | Zusammensetzung zur herstellung von antithrombotischen medizinischen erzeugnissen. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2235678A1 (en) * | 1973-07-02 | 1975-01-31 | Merck & Co Inc | Topical antipsoriasis agents - contg. prostaglandin E1 or E2 |
-
1978
- 1978-05-18 SE SE7805707A patent/SE443716B/sv not_active IP Right Cessation
- 1978-05-18 NL NL7805402A patent/NL7805402A/xx not_active Application Discontinuation
- 1978-05-18 DE DE19782821737 patent/DE2821737A1/de active Granted
- 1978-05-18 HU HU78WE576A patent/HU180548B/hu unknown
- 1978-05-18 CH CH541678A patent/CH643458A5/de not_active IP Right Cessation
- 1978-05-18 JP JP5946078A patent/JPS542335A/ja active Pending
- 1978-05-18 FR FR7814729A patent/FR2390964A1/fr active Granted
- 1978-05-22 IT IT49485/78A patent/IT1105506B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| IT7849485A0 (it) | 1978-05-22 |
| CH643458A5 (en) | 1984-06-15 |
| FR2390964A1 (fr) | 1978-12-15 |
| DE2821737C2 (enExample) | 1988-05-19 |
| NL7805402A (nl) | 1978-11-22 |
| JPS542335A (en) | 1979-01-09 |
| DE2821737A1 (de) | 1978-11-30 |
| IT1105506B (it) | 1985-11-04 |
| HU180548B (en) | 1983-03-28 |
| FR2390964B1 (enExample) | 1980-07-11 |
| SE7805707L (sv) | 1978-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1461039B1 (en) | Pharmaceutical compositions comprising cilostazol and an adenosine uptake inhibitor | |
| CA2450777C (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
| US20010041673A1 (en) | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | |
| EP1097709A2 (en) | Use of corticotropin releasing factor antagonists for treating syndrome X | |
| KR20150079745A (ko) | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 | |
| JPH0367045B2 (enExample) | ||
| Casals‐Stenzel et al. | Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity | |
| EP2459173A1 (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| KR101176110B1 (ko) | 문맥성 고혈압의 예방 및/또는 치료 | |
| US4337254A (en) | Pharmaceutical compositions | |
| CA2631740A1 (en) | Methods and compositions for the treatment of disease | |
| SE443716B (sv) | Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor | |
| KR101603279B1 (ko) | 프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| EP0667349A1 (en) | Depression remedy | |
| GB1601034A (en) | Pharmaceutical compositions | |
| KR20190085946A (ko) | 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신 손상 예방 또는 치료용 약학적 조성물 | |
| US3987173A (en) | Pharmaceutical preparations comprising vincamine alkaloids and dihydroergocristine | |
| ES2260061T3 (es) | Composiciones farmaceuticas para trastornos relacionados con la alimentacion. | |
| WO2005027910A1 (en) | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias | |
| EP0011828A1 (en) | Pharmaceutical combinations including hydantoin derivatives, pharmaceutical formulations containing the combinations and methods of making the formulations | |
| EP0338010B1 (en) | Pharmaceutical compositions for treatment of hyperproliferate skin disease | |
| AU4281993A (en) | Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith | |
| HK1172242A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| HK1172242B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| HU193280B (en) | Process for preparing novel hidantane derivatives and compositions comprising the same as active substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7805707-2 Effective date: 19890525 Format of ref document f/p: F |